Innoviva

Innoviva

Yahoo Finance • 8 days ago

As U.S. profit margins near record highs, these small-cap stocks lead on profitability

[Growth bar graph] Dougal Waters As U.S. corporate profit margins remain near historic highs, investors are increasingly looking for companies that can translate strong operating performance into sustained earnings growth. Recent data fr... Full story

Yahoo Finance • 9 days ago

These small-cap healthcare stocks pair revenue growth with attractive valuations

[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images Healthcare stocks have remained in focus as investors look for companies that can deliver strong operational growth... Full story

Yahoo Finance • 25 days ago

Innoviva to Participate in Upcoming Investor Conferences

BURLINGAME, Calif., June 01, 2026--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platfo... Full story

Yahoo Finance • 27 days ago

Innoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million More

Key Points Dauntless Investment Group bought 116,863 shares of Innoviva in an estimated trade of $2.52 million last quarter. The quarter-end position value rose by $2.74 million, reflecting both trading and price movements. The post-trade... Full story

Yahoo Finance • 3 months ago

Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential

Sarissa Capital Management established a new position in Biohaven Ltd.(NYSE:BHVN) during the fourth quarter, acquiring 513,184 shares worth $5.79 million at quarter’s end, according to a February 17, 2026, SEC filing. What happened Accor... Full story

Yahoo Finance • 3 months ago

Mutiny At Aurinia Pharmaceuticals? Biotech Soars On C-Suite Shake-Up.

Aurinia Pharmaceuticals announced a complete overhaul of its C-suite on Monday, sparking both the biotech stock and hopes of an acquisition. Continue Reading... Full story

Yahoo Finance • 4 months ago

Innoviva, Inc. (INVA): A Bull Case Theory

We came across a bullish thesis on Innoviva, Inc on Deep-Value Stocks’s Substack. In this article, we will summarize the bulls’ thesis on INVA. Innoviva, Inc's share was trading at $22.48 as of February 11th. INVA’s trailing and forward P/... Full story

Yahoo Finance • 4 months ago

Celldex Therapeutics Stock Earns 88 RS Rating

On Thursday, Celldex Therapeutics stock received an upgrade to its Relative Strength (RS) Rating, from 63 to 88. This unique rating tracks technical performance by using a 1 (worst) to 99 (best) score that identifies how a stock's price ac... Full story

Yahoo Finance • 4 months ago

AtaiBeckley names Michael Faerm as finance chief

AtaiBeckley names Michael Faerm as finance chief Proactive uses images sourced from Shutterstock AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC) announced that it has appointed Michael Faerm as chief financial officer, effective March 9, 2026, as... Full story

Yahoo Finance • 6 months ago

H.C. Wainwright Lifts PT on Innoviva (INVA) to $46 From $45, Keeps a Buy Rating

Innoviva, Inc. (NASDAQ:INVA) is one of the best small cap stocks to buy with huge upside potential. Innoviva, Inc. (NASDAQ:INVA) received a rating update from H.C. Wainwright on December 16, who lifted the price target to $46 from $45 whil... Full story

Yahoo Finance • 6 months ago

FDA Approves Innoviva's NUZOLVENCE, First-in-Class Oral Treatment For Gonorrhea

(RTTNews) - Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (INVA), announced that the U.S. Food and Drug Administration approved NUZOLVENCE (zoliflodacin) for oral suspension, a first-in-class, single-dose oral medication... Full story

Yahoo Finance • 8 months ago

Innoviva, Inc. Reports Increase In Q3 Income

(RTTNews) - Innoviva, Inc. (INVA) reported earnings for its third quarter that Increased, from last year The company's bottom line totaled $89.91 million, or $1.08 per share. This compares with $1.21 million, or $0.02 per share, last yea... Full story

Yahoo Finance • 8 months ago

Top FDA official Tidmarsh resigns after comments on kidney drug, HHS probe

[Headquarters of US Food and Drug Administration (FDA)] Grandbrothers George Tidmarsh has lost his job as director of the U.S. FDA's Center for Drug Evaluation and Research amid accusations that he leveled false statements against a Canad... Full story

Yahoo Finance • 10 months ago

Innoviva Inc (NASDAQ:INVA): A Prime Candidate for Value Investors Seeking Undervalued Stocks

In value investing, finding companies trading below their intrinsic value while having good fundamentals is a core strategy. The method depends on picking stocks that are not only priced well compared to their earnings and assets but also... Full story

Yahoo Finance • 10 months ago

Innoviva Inc (NASDAQ:INVA) Recognized as a "Decent Value" Stock with Strong Valuation and Growth Potential

Innoviva Inc (NASDAQ:INVA [https://www.chartmill.com/stock/quote/INVA]) has been recognized using a "Decent Value" screening method, which focuses on stocks with good valuation metrics while maintaining acceptable profitability, financial... Full story

Yahoo Finance • 10 months ago

Oppenheimer initiates Inova Technology stock with Outperform rating

Investing.com - Oppenheimer has initiated coverage on Inova Technology, Inc. (NASDAQ:INVA) with an Outperform rating and a price target of $35.00. According to InvestingPro data, the company maintains a "GREAT" financial health score of 3.... Full story

Yahoo Finance • last year

Basilea announces commercial availability of antibiotic Zevtera® (ceftobiprole) in the United States

Allschwil, Switzerland, May 20, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today th... Full story

Yahoo Finance • last year

Basilea gibt Verkaufsstart seines Antibiotikums Zevtera® (Ceftobiprol) in den USA bekannt

Allschwil, 20. Mai 2025 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren Infektionen durch Bakterien oder Pilze erkr... Full story

Yahoo Finance • 3 years ago

Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics

Signs new $25 million credit agreement and extension of existing secured convertible credit agreement Appoints world‐renowned healthcare leader Dr. Deborah L. Birx as Chief Executive Officer MARINA DEL REY, Calif., July 11, 2023 /PRNewsw... Full story

Yahoo Finance • 3 years ago

12 Best Extremely Profitable Stocks to Buy

In this piece, we will take a look at 12 best extremely profitable stocks to buy. If you want to skip our economic and market analysis and jump ahead to the top five stocks in the list, take a look at 5 Best Extremely Profitable Stocks to... Full story